What is the management approach for Henoch-Schonlein purpura (HSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Henoch-Schönlein Purpura

For most children with HSP, supportive care alone is sufficient as the disease spontaneously resolves in 94% of children and 89% of adults, with treatment focused on symptom control and monitoring for renal complications. 1, 2

Initial Diagnostic Confirmation

  • Diagnose HSP clinically when palpable purpura is present plus at least one of the following: renal involvement (hematuria and/or proteinuria), arthralgia/arthritis, or abdominal pain 1
  • Perform urinalysis with microscopy at presentation to assess for proteinuria, red blood cell casts, and dysmorphic red blood cells indicating glomerular involvement 1
  • Obtain basic metabolic panel (BUN, serum creatinine) and complete blood count with platelets to assess renal function and rule out thrombocytopenia 1
  • Measure blood pressure as hypertension indicates more severe renal involvement 1

Symptomatic Management

Joint and Cutaneous Symptoms

  • Use acetaminophen (paracetamol) as first-line analgesic, avoiding NSAIDs like ketorolac (Toradol) which can cause acute kidney injury in patients with renal impairment 1
  • Consider oral prednisone 1-2 mg/kg daily for two weeks for severe joint pain and widespread cutaneous symptoms 1, 2
  • For persistent purpura and pain, colchicine 1 mg/day for at least six months may be beneficial 1

Gastrointestinal Symptoms

  • Oral prednisone 1-2 mg/kg daily for two weeks is recommended for severe abdominal pain and gastrointestinal hemorrhage 2, 3
  • A low-antigen-content (LAC) diet strictly followed for 4-8 weeks may improve symptoms and can be used in conjunction with other treatments 1
  • Monitor for complications including intussusception and gastrointestinal bleeding 4

Renal Disease Management Algorithm

Initial Monitoring (All Patients)

  • Monitor all HSP patients for six months with regular urinalysis 5
  • A normal urinalysis on day 7 has 97% negative predictive value for normal renal outcome 5
  • Prioritize intensive monitoring for patients with abnormal urine findings on day 7 5

Persistent Proteinuria

  • For persistent proteinuria, initiate ACE inhibitors or ARBs as first-line therapy 1
  • For persistent proteinuria >1 g/day per 1.73 m² after ACE inhibitor/ARB trial and GFR >50 ml/min per 1.73 m², add a 6-month course of corticosteroid therapy 1

Severe Nephritis

  • For crescentic HSP with nephrotic syndrome and/or deteriorating kidney function, treat with steroids and cyclophosphamide 1, 4
  • Alternative immunosuppressants include azathioprine, cyclosporine, tacrolimus, or mycophenolate mofetil/mycophenolic acid when cyclophosphamide is contraindicated due to side effects 1

Adult Patients

  • Apply the same treatment approach as in children for adults with HSP nephritis 1

Important Caveats

  • Do not use prophylactic corticosteroids to prevent HSP nephritis - strong evidence shows this is not effective 1
  • Older patients are at higher risk for renal complications requiring specialist referral 5
  • Long-term prognosis depends entirely on severity of renal involvement, with end-stage renal disease occurring in 1-5% of patients 2
  • Adolescents may have more severe presentations requiring close monitoring for gastrointestinal, cardiac, renal, and neurological complications 4
  • Renal ultrasound is the preferred imaging modality if renal biopsy is being considered for severe nephritis 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.